Weight medicines need their own set of questions

• Ask for the ingredient and the finished product together.
• Ask which use in the product label relates to your concern.
• Ask whether the proposed form is the form studied or approved.

GLP-1 is a natural substance in your body that helps control blood sugar and appetite. Some medicines copy its action; people also use GLP-1 as a name for those medicines.

In the US record dated September 26, 2026, there are approved semaglutide products (Ozempic, Wegovy). Tirzepatide products (Mounjaro, Zepbound) also have approvals.

Compounding is preparation to order for a patient. It does not produce an FDA-approved generic of semaglutide or tirzepatide, under the position checked September 26, 2026.

• What rule allows the maker to prepare this exact medicine?
• What need does the prescriber say the change meets for me?

At the September 26, 2026 check, the shortage list named neither tirzepatide nor semaglutide injection; earlier shortages had allowed wider compounding.

An empty shelf locally does not establish a national FDA shortage.

Adding a vitamin can still leave a preparation classed as essentially a copy; that was FDA’s stated approach in the September 26, 2026 record.

Neither retatrutide nor cagrilintide may be used for compounding under federal law, according to FDA’s position recorded on September 26, 2026.